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Posttranslational modification of proteins can greatly enrich the diversity of the protein world beyond the com bination of twenty amino acids encoded by the direction of the genetic information. Protein methylation can occur on various amino acid side chains such as glutamyl and isoaspartyl residues to form base labile methylesters or arginine or lysine residues to form chemically base-stable methylamines (1) . It has been demonstrated that the majority of methyl-accepting sites are occupied in cells (2) . To obtain methyl-accepting proteins with empty methyl-accepting sites for further studies, general inhibi tion of protein methylation can be accomplished by treat ing cells with methyltransferase inhibitors. For example, adenosine dialdehyde (AdOx), an indirect inhibitor that can be incorporated by cells, has been routinely used. AdOx inhibits S-adenosyl-L-homocystein hydrolase, resulting in the accumulation of S-adenosyl-L-homo cystein (Adoicy), a product inhibitor of methyltrans ferases that utilize S-adenosyl-L-methionine (AdoMet) as the methyl group donor (3, 4) . In this way, the methyl accepting polypeptides can be retained in hypomethyl (19, 20) .
HeLa cells have been used for hnRNP protein methyla tion studies (17) and other investigations related to pro tein methylation (20) . The origin of the hypomethylated proteins accumu lated upon AdOx treatment was further studied. HeLa cells were incubated with a translation inhibitor, cycloheximide (CHX), at the same time as the AdOx treatment. Since cells appeared to die upon double treat ment for 12 h, we performed the experiments for periods of 1, 3 and 6 h. As shown in Fig. 1b , the AdOx treatment can accumulate methyl-accepting proteins in short inter vals of 3 and 6 h. However, the presence of CHX com pletely blocked the accumulation of methyl-accepting proteins by AdOx treatment at 3 and 6 h. Cycloheximide treatment did not effect the type I arginine methyltrans ferase activity in HeLa cells as assayed by the addition of an exogenous methyl-accepting protein, fibrillarin (Fig.  lc) . Thus the disappearance of methyl-accepting proteins by CHX treatment is probably due not to reduced protein methyltransferase activity in the extract but to the block age of new protein synthesis. The results indicated that the methyl-accepting proteins accumulated for in vitro methylation by AdOx treatment are most likely to be newly synthesized during the incubation period.
Effects of AdOx Treatment on In Vivo Methylation-In vivo protein methylation in mammalian cells with [methyl-3H] methionine has been used to evaluate the protein methylation under native conditions (17, 18) . To prevent the incorporation of radioactive methyl groups into proteins by translation but not posttranslational modification, protein synthesis inhibitors have to be included throughout the in vivo methylation period. Var ious methyl-accepting proteins were detected in earlier studies, which somehow seems not to agree with our results in Fig. lb suggesting that methyl-accepting sites are on newly synthesized proteins. We performed in vivo methylation in HeLa cells following the protocol of Liu et al. (17) and as reported previously, detected many labeled polypeptides (Fig. 2) . We then treated the cells with AdOx prior to the in vivo methylation. Except for few polypeptides, the pattern of the signals of AdOx-pre treated cells was basically the same as that of the untreated ones. However, addition of AdOx for 24 h before in vivo methylation clearly increased the labeling of polypeptides of molecular mass between 40 to 100 kDa. No new protein synthesis was detected under the in vivo methylation conditions as monitored by incubation with 35S-Met (data not shown) . The methyl groups were proba bly present on the unmodified proteins newly synthe sized before the in vivo methylation period in the pres ence of CHX.
In addition, when AdOx was present in the labeling medium after the 24-h pretreatment, the elevated in vivo methylation pattern appeared to be suppressed back to a low level. When the in vivo labeling was followed by a 12 h chase in the non-radioactive medium, the majority of the in vivo labeled polypeptides were of similar level, indicating that the modified proteins were rather stable. Similar results were obtained from the 12-h chase exper iments of no AdOx treatment or AdOx-pretreatment/ labeling samples (data not shown).
The Level of Methylarginine-Containing Proteins in AdOx-Treated or Untreated Cell Extracts Detected by Methylarginine-Specific Antibodies-AdOx can accumu late proteins in hypomethylated states for in vivo and in vitro methylation.
Nevertheless, the fraction of the AdOx-affected polypeptides in the whole methyl-modified protein is unknown.
Protein arginine methylation accounts for the majority of AdOx-stable protein methyl ation in rat pheochromocytoma PC 12 cells (5) and human lymphoblastoid cells (6, 7) . We also found that the major methyl-accepting substrates accumulated by AdOx treat ment can be recognized by the predominant protein arginine methyltransferase PRMT1 and are likely to be modified to form methylarginines (data not shown). We thus determined the level of total methylarginine-con taining proteins in the extracts by Western blot analysis. Methylarginine-specific antibodies SYM 10, SYM11 and ASYM24 are rabbit polyclonal antibodies against alter native RG sequences containing symmetric dimethyl arginine (sDMA), SmD3 RG sequences containing sDMA, and alternative RG sequences containing asymmetric dimethylarginine (aDMA) in all the arginyl positions, respectively (23) . Another antibody, 7E6, is specific for monomethylarginine (MMA) and aDMA (24) . As shown in Fig. 3 , reduced recognition of certain specific polypep tides by SYM10, SYM11, ASYM24 was observed for the AdOx-treated cell extracts. For SYM10 recognition, the intensity of the strongest 30-kDa signal was the same in both samples, while most of the signals above 36 kDa were reduced in the AdOx-treated sample (Fig. 3a) . For SYM11, except for the highest signal above 113 kDa, most of the signals were slightly stronger in the untreated sample (Fig. 3b) . The polypeptides with molec ular mass of 80, 28 and 16 kDa are probably the previ ously identified p80 coilin, SmB and SmD3, respectively (25) . As for AYM24, generally the signals appeared to be slightly reduced in the AdOx-treated samples, probably including Sam68 at the molecular mass of 68 kDa (20) . However, no difference was detected between the AdOx treated and untreated cell extracts using the 7E6 methy larginine-specific antibodies (Fig. 3d) . Whether this anti body might cross-react with certain other epitopes, thus masking minor differences in the level of methyl arginines, needs more investigation.
Treatment of HeLa Cells with a Proteosome Inhibitor ALLN Does Not Affect AdOx-Mediated Accumulation of Hypomethylated Proteins-The in vivo labeled proteins appeared to be rather stable in our 12-h chase period. We then investigated whether the normally methylated pro teins might be degraded rapidly when rendered unmeth ylated by AdOx-treatment.
N-acetyl-leu-leu-norleucinal (ALLN) is an inhibitor that blocks proteolytic activity of both type I calpain and the 26 S proteosome. We treated the cells with ALLN to evaluate the effect of protein deg radation on the accumulation of methyl-accepting sites by AdOx treatment. No significant changes to the AdOx induced hypomethylation pattern upon the addition of ALLN for 24 h were observed (Fig. 4) . Thus, under our experimental conditions, ALLN-blocked proteosome deg In comparison, the proteosome inhibitor ALLN did not change the appearance of methyl-accepting proteins upon AdOx treatment. This result indicated that the accumulated hypomethylated proteins probably are not subject to rapid proteosome degradation, otherwise inhi bition of protein degradation by ALLN should accumu late more of these sites.
Our results represent the base-stable methylation of the AdOx-accumulated methyl-accepting proteins cata lyzed by all endogenous methyltransferases in the extracts. Base-labile methylation that cannot survive the mild alkaline conditions of SDS-PAGE, such as carboxyl methylation, can be excluded; but C-terminal carboxyl methylation and N-methylation such as lysyl or arginyl methylation could not be distinguished (1) . The irreversi ble modification on the guanidino nitrogen of the arginyl residues is known to account for the majority of the AdOx-accumulated stable protein methylation events in PC 12 and lymphoblastoid cells (5, 6) . We detected limited but consistent reduction of the methylarginine-contain ing proteins in AdOx-treated samples compared to untreated ones by use of sDMA and aDMA-specific anti bodies. Specifically, decreased signals that probably cor respond to methylation of coilin, SmB and Sm D3 were detected in AdOx-treated extracts. It is possible that since the cells treated with AdOx are of high confluency, most of the methyl-accepting proteins are already syn thesized and methylated. If they are stable and turn over slowly, as indiiicated by the chase/in vivo methylation experiments, the newly synthesized proteins will be responsible for only a small fraction of the total pool of the methyl-accepting proteins in the cell, and the differ ence will be barely detectable. This is consistent with our inability to detect differences between the overall protein patterns from AdOx treated cells and untreated cells by two-dimensional gel electrophoresis (26) . Thus, AdOx probably only affects a small portion of the total methyl containing proteins, at least for the methylarginine-con taining proteins.
However, application of AdOx to inhibit specific pro tein methylation has already been shown in different cells. For example, we demonstrated that certain methyl arginine-containing trypsin-digested peptides of hnRNPA2/B1 could be detected from AdOx-untreated lymphoblastoid cells but not from AdOx-treated cells (26) . Nichols et al. also showed that of AdOx could affect the subcellular localization of hnRNPA2/B1 in HEK293 cells, presumably by affecting the methylation in the RGG domain (27) . These investigations support the appropriateness of applying of AdOx treatment in spe cific protein methylation studies.
In summary, although AdOx treatment had been fre quently used to accumulate methyl-accepting proteins for further in vitro methylation, the protein methylation inhibition is restricted to newly translated proteins dur ing the treatment, which blocks only a small fraction of protein methylation in cells. In this study, we also show that AdOx can be applied to in vivo methylation as well as in vitro methylation. The timing of the AdOx treat ment can be adjusted to enhance or to inhibit the in vivo methylation. In combination with chase experiments, in vivo methylation can be applied to follow the methylation of methyl-accepting proteins. 
